Physician profile
Sheetal Shah
NPI 1861620072
$12,440.31
in general payments reported to CMS, 2019-2025
76 companies · $1,737 in 2025
The $1,737 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,253 · 2020: $907 · 2021: $1,991 · 2022: $2,490 · 2023: $2,112 · 2024: $1,950 · 2025: $1,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,799.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,587.25 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Pfizer INC. | $870.68 | 2019-2025 | |
| Amgen INC. | $667.99 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.64 | 2019-2025 | Jardiance, Synjardy |
| Esperion Therapeutics, INC. | $537.75 | 2020-2025 | Nexletol |
| Bausch Health US, LLC | $499.35 | 2019-2025 | Aplenzin, Wellbutrin |
| Astrazeneca Pharmaceuticals Lp | $469.63 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Otsuka America Pharmaceutical, INC. | $442.25 | 2019-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $372.20 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $368.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $355.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $350.75 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $327.98 | 2021-2025 | |
| Astellas Pharma US INC | $279.31 | 2019-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $266.09 | 2021-2024 | Austedo Xr, Ajovy |
Show all 76 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.